The purpose of this study was to quantify flutriciclamide’s uptake patterns in the brains of control subjects and patients with CCM using TSPO PET and compare these uptake levels caused by neuroinflammation with iron deposition assessed via quantitative susceptibility mapping (QSM) (22, 42–44). The gene discussed is TSPO; the disease is cerebral cavernous malformation.